AR041255A1 - Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso. - Google Patents

Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso.

Info

Publication number
AR041255A1
AR041255A1 ARP030103331A ARP030103331A AR041255A1 AR 041255 A1 AR041255 A1 AR 041255A1 AR P030103331 A ARP030103331 A AR P030103331A AR P030103331 A ARP030103331 A AR P030103331A AR 041255 A1 AR041255 A1 AR 041255A1
Authority
AR
Argentina
Prior art keywords
alkyl
compound
alkoxy
amino
formula
Prior art date
Application number
ARP030103331A
Other languages
English (en)
Inventor
Ann Marie Madera
Robert James Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR041255A1 publication Critical patent/AR041255A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Abstract

La presente proporciona un compuesto de fórmula (1) o una sal. La presente proporciona composiciones que comprenden, métodos de uso, y métodos para la preparación de un compuesto de fórmula (1) Reivindicación 1: Un compuesto de fórmula (1) o unasal farmacéuticamente aceptables de la misma, en donde: n es 0, 1 ó 2; p es 1 ó 2; R1 es arilo o heteroarilo; R2 es heterociclilo; R3 es hidrógeno, alquilo, o -C(=O)-R5, donde R5 es alquilo, alcoxilo, arilo, o ariloxilo; y cada R4 esindependientemente hidrógeno, hidroxilo, ciano, alquilo, alcoxilo, tioalquilo, tioalquilo, halo, haloalquilo, hidroxialquilo, nitro, alcoxicarbonilo, alquilcarbonilo, alquilsulfonilo, arilsulfonilo, haloalquilsulfonilo, amino, alquilamino,dialquilamino, alquil(aril)amino, alquilaminocarbonilo, alquilcarbonilamino, alquilcarbonil(alquilamino), alquilaminosulfonilo, alquilsulfonilamino o metilenodioxihidrógeno, alquilo, alcoxilo, halo, o haloalquilo.
ARP030103331A 2002-09-17 2003-09-15 Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso. AR041255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41123902P 2002-09-17 2002-09-17

Publications (1)

Publication Number Publication Date
AR041255A1 true AR041255A1 (es) 2005-05-11

Family

ID=32030655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103331A AR041255A1 (es) 2002-09-17 2003-09-15 Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso.

Country Status (29)

Country Link
US (1) US7247651B2 (es)
EP (1) EP1587788B9 (es)
JP (1) JP4327091B2 (es)
KR (1) KR100686758B1 (es)
CN (1) CN1314669C (es)
AR (1) AR041255A1 (es)
AT (1) ATE362469T1 (es)
AU (1) AU2003273855B2 (es)
BR (1) BR0314352A (es)
CA (1) CA2496765A1 (es)
DE (1) DE60313895T2 (es)
DK (1) DK1587788T3 (es)
ES (1) ES2287518T3 (es)
GT (1) GT200300199A (es)
HK (1) HK1083500A1 (es)
HR (1) HRP20050229A2 (es)
MX (1) MXPA05002696A (es)
MY (1) MY138826A (es)
NO (1) NO20050666L (es)
NZ (1) NZ537982A (es)
PA (1) PA8582201A1 (es)
PE (1) PE20050054A1 (es)
PL (1) PL376020A1 (es)
PT (1) PT1587788E (es)
RU (1) RU2327685C2 (es)
TW (1) TWI249402B (es)
UY (1) UY27980A1 (es)
WO (1) WO2004026830A1 (es)
ZA (1) ZA200501306B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209872B1 (pl) 2002-03-27 2011-10-31 Glaxo Group Ltd Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
PL1701940T3 (pl) * 2003-12-23 2008-11-28 H Lundbeck As Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
ES2643615T3 (es) 2004-09-30 2017-11-23 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2010509259A (ja) * 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー インドール及びベンゾフラン２−カルボキサミド誘導体
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN103288707B (zh) * 2013-05-28 2015-12-23 浙江大学 一种3-苯巯基吲哚衍生物的制备方法
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
CA2953004C (en) 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
EP0982304B1 (en) 1998-06-30 2002-10-02 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
FR2788772B1 (fr) * 1999-01-26 2001-03-02 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
JP4187642B2 (ja) * 2001-06-07 2008-11-26 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６受容体親和性を有する新規インドール誘導体
BR0210411A (pt) * 2001-06-15 2004-08-17 Hoffmann La Roche Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6
EP1414442A1 (en) * 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物

Also Published As

Publication number Publication date
NO20050666L (no) 2005-03-11
PE20050054A1 (es) 2005-02-18
MXPA05002696A (es) 2005-05-05
DK1587788T3 (da) 2007-09-24
PT1587788E (pt) 2007-08-20
TWI249402B (en) 2006-02-21
AU2003273855B2 (en) 2009-01-15
TW200410685A (en) 2004-07-01
US20040063724A1 (en) 2004-04-01
ES2287518T3 (es) 2007-12-16
US7247651B2 (en) 2007-07-24
NZ537982A (en) 2007-05-31
KR100686758B1 (ko) 2007-02-26
PA8582201A1 (es) 2004-04-23
EP1587788B9 (en) 2007-10-24
MY138826A (en) 2009-07-31
RU2005111587A (ru) 2005-11-20
ZA200501306B (en) 2006-05-31
JP2006503052A (ja) 2006-01-26
HRP20050229A2 (hr) 2006-04-30
DE60313895D1 (de) 2007-06-28
EP1587788B1 (en) 2007-05-16
AU2003273855A1 (en) 2004-04-08
GT200300199A (es) 2006-08-22
EP1587788A1 (en) 2005-10-26
KR20050057357A (ko) 2005-06-16
DE60313895T2 (de) 2008-01-17
CN1681782A (zh) 2005-10-12
CN1314669C (zh) 2007-05-09
ATE362469T1 (de) 2007-06-15
BR0314352A (pt) 2005-07-19
RU2327685C2 (ru) 2008-06-27
JP4327091B2 (ja) 2009-09-09
HK1083500A1 (en) 2006-07-07
WO2004026830A1 (en) 2004-04-01
CA2496765A1 (en) 2004-04-01
UY27980A1 (es) 2004-03-31
PL376020A1 (en) 2005-12-12

Similar Documents

Publication Publication Date Title
AR041255A1 (es) Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso.
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
CR8861A (es) Nuevos derivados piperidilo de quinazolina e isoquinolina
AR041256A1 (es) Indoles sustituidos en posicion 2,4 y su uso como moduladores de 5-ht6
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
RS74904A (en) Substituted pyridinones as modulators of p38 map kinase
LU92146I2 (fr) Dasatinib et ses sels pharmaceutiquement acceptables
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
DOP2005000022A (es) "derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina"
ATE284690T1 (de) Antithrombotische diamine
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
BR0012697A (pt) Inibidores da diferenciação de th2
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
NO993027D0 (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
ECSP045484A (es) Derivados de carbamato de quinuclidina
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
AR050711A1 (es) Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central
AR035945A1 (es) Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure